UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

Breast cancer research and treatment, 2019-12, Vol.178 (3), p.597-605

2019

Volltextzugriff (PDF)

H. Wijfjes, G. Voerman (eds.), Mediatization of Politics in History

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2011-01, Vol.126 (2), p.137-138

Beelen, K.

2011

Volltextzugriff (PDF)

St. Gallen endocrine response classes predict recurrence rates over time

Breast (Edinburgh), 2015-12, Vol.24 (6), p.705-712

2015

Volltextzugriff (PDF)

CYP2C192 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

Breast cancer research and treatment, 2013-06, Vol.139 (3), p.649-655

2013

Volltextzugriff (PDF)

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

Cancer cell, 2007-10, Vol.12 (4), p.395-402

2007

Volltextzugriff (PDF)

1405 POSTER DISCUSSION Cyp2C192 Polymorphism Predicts Benefit of Adjuvant Tamoxifen in ER Positive Postmenopausal Breast Cancer Patients

European journal of cancer (1990), 2011, Vol.47, p.S170-S171

2011

Volltextzugriff (PDF)

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: primary outcomes from the randomized phase III OLIGO study

European journal of cancer (1990), 2024-12, Vol.213, p.115083, Article 115083

2024

Volltextzugriff (PDF)

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD4-12-PD4-12

2018

Volltextzugriff (PDF)

LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)

Annals of oncology, 2021-09, Vol.32, p.S1291-S1292

2021

Volltextzugriff (PDF)

H. Wijfjes, G. Voerman (eds.), Mediatization of Politics in History

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2011-01, Vol.126 (2), p.137-138

K. Beelen

2011

Volltextzugriff (PDF)

H. Wijfjes, G. Voerman (eds.), Mediatization of Politics in History

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2011-01, Vol.126 (2)

K. Beelen

2011

Volltextzugriff (PDF)

H. Wijfjes, G. Voerman (eds.), Mediatization of Politics in History

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2011-01, Vol.126 (2)

K. Beelen

2011

Volltextzugriff (PDF)

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-11-OT2-01-11

2017

Volltextzugriff (PDF)

Are St. Gallen endocrine response classes predictive for recurrence rates over time?

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.576-576

2011

Volltextzugriff (PDF)

Abstract P6-17-19: What to do with trastuzumab therapy after achieving radiological complete remission (rCR) in HER2+ metastatic breast cancer (MBC)?

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-17-19

2019

Volltextzugriff (PDF)

Abstract PD01-02: Increased expression of phosporylated mTOR in metastatic breast tumors compared to primary tumors in patients who received adjuvant endocrine therapy

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.PD01-02-PD01-02

2012

Volltextzugriff (PDF)

“TRIASUS”: A Web Based Information Management System for Sharing Pre- And Post-Transplantation Clinical, HLA and Chimaerism Data

Biology of blood and marrow transplantation, 2009-02, Vol.15 (2), p.98-98

2009

Volltextzugriff (PDF)

Abstract PD01-03: Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.PD01-03-PD01-03

2012

Volltextzugriff (PDF)

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

Breast cancer research and treatment, 2013-06, Vol.139 (3), p.649-655

2013

Volltextzugriff (PDF)

Relapse of chronic inflammatory demyelinating polyneuropathy following treatment with zoledronic acid

Nederlands tijdschrift voor geneeskunde, 2017, Vol.161, p.D1747

2017

Volltextzugriff (PDF)

Nipple secretion: a concern for the family physician?

Nederlands tijdschrift voor geneeskunde, 1991-11, Vol.135 (46), p.2171

1991

Volltextzugriff (PDF)

MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease

Leukemia, 2014-04, Vol.28 (4), p.970-973

2014

Volltextzugriff (PDF)

Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds

PloS one, 2017-06, Vol.12 (6), p.e0179350-e0179350

2017

Volltextzugriff (PDF)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Leukemia, 2017-11, Vol.31 (11), p.2398-2406

2017

Volltextzugriff (PDF)

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Breast cancer research : BCR, 2019-08, Vol.21 (1), p.90-90, Article 90

2019

Volltextzugriff (PDF)

1 – 25 von 593

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(533)
Mit Volltextzugriff
(511)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Astronomy And Astrophysics
(84)
Blood
(36)
Astronomy & Astrophysics
(29)
Epj Web Of Conferences
(20)
Bone Marrow Transplantation
(19)
Epj Web Conf
(18)
Leukemia
(14)
Physica
(12)
The Astrophysical Journal
(12)
Monthly Notices Of The Royal Astronomical Society
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?

H. Wijfjes, G. Voerman (eds.), Mediatization of Politics in History

St. Gallen endocrine response classes predict recurrence rates over time

CYP2C192 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

1405 POSTER DISCUSSION Cyp2C192 Polymorphism Predicts Benefit of Adjuvant Tamoxifen in ER Positive Postmenopausal Breast Cancer Patients

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: primary outcomes from the randomized phase III OLIGO study

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

LBA18 POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)

H. Wijfjes, G. Voerman (eds.), Mediatization of Politics in History

H. Wijfjes, G. Voerman (eds.), Mediatization of Politics in History

H. Wijfjes, G. Voerman (eds.), Mediatization of Politics in History

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Are St. Gallen endocrine response classes predictive for recurrence rates over time?

Abstract P6-17-19: What to do with trastuzumab therapy after achieving radiological complete remission (rCR) in HER2+ metastatic breast cancer (MBC)?

Abstract PD01-02: Increased expression of phosporylated mTOR in metastatic breast tumors compared to primary tumors in patients who received adjuvant endocrine therapy

“TRIASUS”: A Web Based Information Management System for Sharing Pre- And Post-Transplantation Clinical, HLA and Chimaerism Data

Abstract PD01-03: Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

Relapse of chronic inflammatory demyelinating polyneuropathy following treatment with zoledronic acid

Nipple secretion: a concern for the family physician?

MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease

Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Suchergebnisse filtern